KPV Peptide — Anti-Inflammatory Research

Last updated: May 2026

KPV is a synthetic tripeptide consisting of the amino acid chain Lys-Pro-Val. It is derived from the C-end tripeptide of alpha-melanocyte-boosting hormone (alpha-MSH). A 13-amino-acid brain peptide produced from the POMC gene. Alpha-MSH has swelling-reducing properties in published research. KPV was isolated to study whether the C-end fragment retains this action. According to a study in the Journal of Research Skin science (2006). KPV reduced NF-kB signaling in skin cell cells exposed to swelling-related stimuli, suggesting. Its swelling-reducing action from the parent alpha-MSH molecule is at least partially encoded in the C-end tripeptide fragment.

Next Level Pharm supplies research-grade KPV tested to at least 99 percent purity by HPLC. Mass spec on every batch. A Certificate of Test with lot number ships with every order for full tracking.

The sections below cover KPV structure, its relationship to alpha-MSH, NF-kB pathway research. Gut model findings. It also covers receptor pathway data and sourcing standards for experts.

Key Takeaways

What it is: KPV is a synthetic Lys-Pro-Val tripeptide derived from the C-end chain of alpha-MSH. Studied for its swelling-reducing action in cells. Animal models.
NF-kB pathway: Published cell studies report that KPV reduces NF-kB nuclear translocation. Downstream pro-swelling-related immune signals output in skin cell and gut skin models.
Gut research: Rodent colitis models show reduced swelling-related markers in KPV-treated groups. Making gut swelling a key research context for this tripeptide.
Receptor pathway: KPV has lower pigment signal receptor link binding than full alpha-MSH. Its pathway may involve inner pathways that do not need standard MCR signaling.
Sourcing standard: Research-grade KPV needs HPLC purity above 99 percent, mass spec tripeptide type check. A lot-exact COA for traceable lab use.

Here is a closer look at KPV pathway, published findings, and sourcing standards for lab research.

What Is KPV and How Was It Derived?

Alpha-MSH is one of several peptide hormones produced by cleavage of proopiomelanocortin (POMC) in the pituitary. Peripheral tissues. It triggers pigment signal receptors (MC1R, MC3R, MC4R, MC5R). Has well-documented swelling-reducing effects in published research. Experts studying alpha-MSH swelling-reducing action sought to find. It is part of the 13-amino-acid chain that drives this effect.

Studies using truncated alpha-MSH fragments found. The C-end chain retained swelling-reducing action even as the N-end receptor-binding domain was removed. KPV (Lys-Pro-Val) is the smallest fragment that consistently showed action in swelling-reducing cell assays. The tripeptide is small enough (about 357 daltons) to cross skin cell membranes. Explains its studied action in gut models. According to a fragment mapping study in the Journal of Dermatological Science (2003). Systematic truncation studies confirmed. KPV was the minimum active chain from the C-end end of alpha-MSH for NF-kB block in skin cell preparations.

How Does KPV Affect NF-kB Signaling?

NF-kB is a nuclear transcription factor. It controls the output of many pro-swelling-related genes including those encoding TNF-alpha, IL-1beta, IL-6. Various chemokines. In resting cells, NF-kB is held inactive in the cytoplasm by blocking IkB proteins. When cells are boosted by swelling-related triggers such as lipopolysaccharide (LPS) or TNF-alpha, IkB is phosphorylated. Degraded, releasing NF-kB to translocate to the nucleus and trigger swelling-related gene transcription.

KPV research in cell models reports that the tripeptide reduces this NF-kB trigger process. According to a study in the Journal of Investigative Dermatology (2006). KPV reduced LPS-induced NF-kB nuclear translocation in human skin cell cells by about 40 percent compared to vehicle controls at a 10 low-level level. The study also measured reduced IL-8. TNF-alpha release in the same cells, consistent with reduced NF-kB transcriptional action.

Browse recovery peptides at Next Level Pharm for COA-tested KPV and linked swelling-reducing research compounds.

What Does Intestinal Inflammation Research Show for KPV?

Gut skin cells are a major research context for KPV since the gut lining is constantly exposed to luminal bacteria. Dietary antigens that trigger NF-kB-mediated swelling-related responses. Disrupted NF-kB control in gut skin cells is a feature of swelling-related bowel models. KPV’s small size. Relative tripeptide stability makes it suitable for luminal delivery in gut research models.

According to a study in the Journal of Pharmacology. Experimental Therapeutics (2008), KPV reduced colon shortening, mucosal myeloperoxidase (MPO) action. Tissue swelling-related scores in a dextran sulfate sodium (DSS) colitis mouse model compared to vehicle-treated controls. MPO action is a marker of neutrophil infiltration into inflamed tissue. The drop in MPO action in KPV-treated animals suggested reduced swelling-related cell recruitment in the colonic mucosa. The study also reported reduced colon NF-kB trigger in treated animals at the protein level.

What Does Receptor Binding Research Show for KPV?

The pigment signal receptor link properties of KPV differ from full-length alpha-MSH. Full alpha-MSH contains the His-Phe-Arg-Trp pharmacophore at positions 6-9 that drives the MC receptor link. KPV, as the C-end tripeptide, lacks this pharmacophore. So has much lower binding binding at MC1R, MC3R. MC4R in standard receptor link assays.

This finding led experts to study whether KPV acts through the inner pathway rather than classical membrane receptor signaling. Published reports suggest KPV may enter cells. Interact directly with NF-kB signaling components or IkB kinase action. According to a mechanistic study in Peptides (2011). KPV swelling-reducing effects persisted in cells pre-treated with pigment signal receptor antagonists. Supporting a receptor-separate inner pathway. The full profile of this pathway remains an active area of published research.

What Do Skin Inflammation Studies Show for KPV?

Skin skin cells are a well-studied cell type for KPV research since they express NF-kB-responsive swelling-related genes. Are easily cultured in vitro. Psoriasis and atopic dermatitis models use skin cell NF-kB trigger as a readout of swelling-related status. Several published studies have used these cell models. The goal is to examine KPV’s effects on skin swelling pathways.

According to a study in the British Journal of Dermatology (2007). KPV reduced skin cell output of IL-6, IL-8. ICAM-1 in cells boosted with TNF-alpha. These three proteins are downstream NF-kB targets and are raised in swelling-related skin terms. The drop was found at KPV levels in the nanomolar to low low-level range. Consistent with the levels used in gut model studies.

What Quality Standards Apply to Research-Grade KPV?

Research-grade KPV needs HPLC purity above 99 percent. The tripeptide’s small size (three amino acids, about 357 daltons) means. Its output byproducts or incomplete chains differ greatly in chromatographic behavior. Are readily separated by RP-HPLC. Mass spec type proof is straightforward for KPV since the molecule weight is low. Precisely calculable from the three-residue chain.

A lot-exact COA provides HPLC purity percentage, mass spec type result, lot number, and storage terms. For experts studying NF-kB pathway control, purity at or above 99 percent is key to ensure. It found pathway changes are attributable to KPV. Not to Lys, Pro, or Val free amino acid contaminants or dipeptide byproducts. It might independently affect immune signals assays.

Frequently Asked Questions

What is KPV peptide?

KPV is a synthetic tripeptide (Lys-Pro-Val) derived from the C-end chain of alpha-melanocyte-boosting hormone (alpha-MSH). It corresponds to the last three amino acids of the 13-residue alpha-MSH chain. Research-grade KPV is studied in lab models of swelling, gut skin science. Pigment signal receptor signaling in the context of swelling-related pathway control.

How does KPV relate to alpha-MSH?

Alpha-MSH is a 13-amino-acid peptide produced from the POMC gene. It triggers pigment signal receptors and has swelling-reducing properties in published research. KPV is the C-end tripeptide fragment of alpha-MSH. Studies show. The C-end tripeptide retains swelling-reducing action from the parent molecule. It cannot bind pigment signal receptors with the same binding as full-length alpha-MSH.

What does KPV research show about inflammation pathways?

Published cell and animal studies report that KPV reduces the trigger of the NF-kB swelling-related signaling pathway. NF-kB controls the output of pro-immune signals including TNF-alpha, IL-6, and IL-1beta. According to a study in the Journal of Research Skin science (2006). KPV reduced NF-kB nuclear translocation in skin cell cells exposed to LPS-induced swelling-related stimuli.

What does intestinal inflammation research show for KPV?

KPV has been studied in rodent colitis models. Published studies report that KPV reduced markers of gut swelling including mucosal myeloperoxidase action. Colon shortening compared to vehicle controls. A 2008 study in the Journal of Drug action. Lab Treatments reported reduced NF-kB trigger in colonic tissue from KPV-treated DSS colitis mice.

Does KPV activate melanocortin receptors directly?

Research indicates. KPV has much lower pigment signal receptor link binding than full-length alpha-MSH since it lacks the His-Phe-Arg-Trp pharmacophore responsible for MC receptor link. Some published studies suggest KPV exerts swelling-reducing effects through an inner pathway. It does not need a pigment signal receptor trigger. The precise receptor-separate pathway is still being characterized in research.

What purity standard applies to research-grade KPV?

Research-grade KPV needs HPLC purity above 99 percent. Mass spec proof of the Lys-Pro-Val tripeptide molecule weight. As a very small tripeptide, KPV has a low molecular weight. It makes mass spec type proof straightforward. A lot-exact Certificate of Test with both HPLC. Mass spec data provides the records standard for traceable lab research.

Is KPV for human use?

The research-grade compound is for lab research only. It is not approved for human use, therapeutic, or diagnostic purposes. All published studies cited in this article used cell culture models or rodent models. The compound should not be given to humans outside of a licensed trial-based trial setting with appropriate control approval.

Where does KPV ship from?

Research-grade KPV ships to all 50 states within the United States. A Certificate of Test with HPLC purity data, mass spec results. Lot number ships with every order to provide full sourcing records for lab research.

Summary

KPV is a synthetic Lys-Pro-Val tripeptide derived from the C-end end of alpha-MSH. Published research links it to NF-kB pathway block in skin cells. Gut skin cell models, and to reduce swelling-related markers in rodent colitis models. The swelling-reducing pathway appears to involve inner signaling rather than standard pigment signal receptor trigger. Research-grade KPV needs HPLC purity above 99 percent, mass spec tripeptide type check. A lot-exact COA for traceable lab research use.

What Should You Do Next?

Browse research-grade KPV at Next Level Pharm for COA-tested options with full HPLC. Mass spec data on every batch.

About the Author

Next Level Pharm Research Team

Alex M covers peer-reviewed findings in peptide science for Next Level Pharm, a US-based supplier of research-grade peptides verified to >=99% purity via HPLC and mass spectrometry on every batch.

Disclaimer: The information provided on this page is for educational and research purposes only. Next Level Pharm’s products are intended for laboratory research use only. They are not intended for human consumption, diagnostic, therapeutic, or medicinal purposes. This content does not constitute medical advice. Always consult a licensed healthcare professional before making any health-related decisions.

KPV Peptide Research: Anti-Inflammatory Pathways and Intestinal Studies